Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications. - Wikidata - wikimedia - TriplyDB

Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.

Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.

http://www.wikidata.org/entity/Q36966228

about

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.Novel psychoactive substances of interest for psychiatry.Serotonin-2C receptor agonists decrease potassium-stimulated GABA release in the nucleus accumbens.Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors.Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.Synthetic Pot: Not Your Grandfather's Marijuana.

P2860

Q28540537-81ABED88-CE3D-4F4D-9FFD-7E5E1CA9D80F Q30251771-AFD89B36-BCBA-4A7E-A808-6670F9635D83 Q34667835-F4A29D4F-40F6-4AAA-BD55-0E2CA833AFCE Q34765276-91E0BABB-0F66-4F57-A48C-7226D29B1211 Q35186684-F096C1A6-B7E3-43C3-BDB1-3266FCE727D4 Q37331831-312D9747-2465-4BC5-9C11-4E7BFBFE2909 Q37707718-8331BA87-93E9-4630-831E-D44EEEAAAB08 Q39052265-115D5D83-4507-4332-B3E3-673FFDA13982 Q39120303-21E67A05-6547-4227-8945-3E9942EACE23

P2860

Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications.

http://www.wikidata.org/entity/Q36966228

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Molecular and behavioral pharm ...... as antipsychotic medications.

@en

type

label

Molecular and behavioral pharm ...... as antipsychotic medications.

@en

prefLabel

Molecular and behavioral pharm ...... as antipsychotic medications.

@en

P1433

Q36966228-6E90D13C-9B22-4D0B-A9DF-8F4E2FDC37A4

P1476

Q36966228-70301877-B698-4FA5-9B3A-12F15D67D0A2

P2093

Q36966228-691A51AB-2D2E-47F2-B279-BCEFB1C61E51

Q36966228-7CAB1C63-154E-49C6-A91A-9BBDF56147C4

Q36966228-8610E809-AA98-4AE9-B2DD-544778842590

Q36966228-9224C736-5B73-4B7F-BE70-DDCE7B468FEA

Q36966228-93855297-E29F-42B9-B290-0DB794EF0EB1

Q36966228-A1E8654F-DE50-4B8E-8AB8-22C2852152C3

Q36966228-E048E9E5-05A8-4487-B25A-9E8AE5E80879

P2860

Q36966228-013272B9-FDDC-4069-B817-1998964B2688

Q36966228-01FEBB8A-B99F-4944-B51A-FD05105B79AF

Q36966228-082800E4-ACC1-4B11-A7FC-2AF36B2926C8

Q36966228-0E2D9D3F-C3D0-425C-8719-CF5C69E3F1F3

Q36966228-1E24D9F1-71E8-47C6-8F57-56E7D54A3669

Q36966228-24572522-567B-401E-8724-7C5D24071AD2

Q36966228-2B2BF87E-123D-490A-BAED-77543CA96649

Q36966228-2C303160-73C3-43D0-B33F-6B0C275D0435

Q36966228-2FBF1058-00BB-46CA-B7D6-8DF49DA72E7D

Q36966228-33689AE9-A7DC-4230-BC6D-81C64CE86EEB

P304

Q36966228-C53FFDF9-E49D-4028-8E7A-BCB5ACDEF13E

P31

Q36966228-83D1D204-0DBF-4B7A-948D-83D6B2D8D310

P356

Q36966228-C860CC4E-E394-42E9-9033-2D0E45464069

P478

Q36966228-1420D81A-1294-4305-B26D-42957D683F4C

P577

Q36966228-CF787996-F14B-4E14-90F4-9E0AA255BB9C

P5875

Q36966228-ABA0E663-7A17-4291-9188-19F020F04F0D

P698

Q36966228-2D225507-A163-4FB9-A3E1-45E2E3F59810

P932

Q36966228-A7B7F306-AA8A-48F9-84B5-D6FB84A0AB97

P356

J.NEUROPHARM.2013.04.051

P1433

Neuropharmacology

P1476

Molecular and behavioral pharm ...... as antipsychotic medications.

@en

P2093

Allison Kuipers

http://www.w3.org/2001/XMLSchema#string

Drake Morgan

http://www.w3.org/2001/XMLSchema#string

Kimberly L Robertson

http://www.w3.org/2001/XMLSchema#string

Krishnakanth Kondabolu

http://www.w3.org/2001/XMLSchema#string

Neil E Rowland

http://www.w3.org/2001/XMLSchema#string

Rajeev Sakhuja

http://www.w3.org/2001/XMLSchema#string

Raymond G Booth

http://www.w3.org/2001/XMLSchema#string

P2860

Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Management of antipsychotic-related weight gain

Identification of a serotonin/glutamate receptor complex implicated in psychosis

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Drugs and valvular heart disease

Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: a combined in vivo electrophysiological and microdialysis study

Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.

Overweight, obesity, and health risk.

P304

274-281

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROPHARM.2013.04.051

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236691201

http://www.w3.org/2001/XMLSchema#string

P698

23665356

http://www.w3.org/2001/XMLSchema#string

P932

3696402

http://www.w3.org/2001/XMLSchema#string